We are live on ! Find out more
SANA icon

Sana Biotechnology

155 hedge funds and large institutions have $639M invested in Sana Biotechnology in 2024 Q3 according to their latest regulatory filings, with 32 funds opening new positions, 42 increasing their positions, 45 reducing their positions, and 25 closing their positions.

New
Increased
Maintained
Reduced
Closed

103% more capital inflows, than outflows

Capital inflows: $52.3M | Capital outflows: $25.8M

52% more call options, than puts

Call options by funds: $9.8M | Put options by funds: $6.42M

28% more first-time investments, than exits

New positions opened: 32 | Existing positions closed: 25

4% more funds holding

Funds holding: 149 → 155 (+6)

1.98% more ownership

Funds ownership: 66.96% → 68.94% (+2%)

7% less repeat investments, than reductions

Existing positions increased: 42 | Existing positions reduced: 45

25% less funds holding in top 10

Funds holding in top 10: 4 → 3 (-1)

Holders
155
Holders Change
+6
Holders Change %
+4.03%
% of All Funds
2.22%
Holding in Top 10
3
Holding in Top 10 Change
-1
Holding in Top 10 Change %
-25%
% of All Funds
0.04%
New
32
Increased
42
Reduced
45
Closed
25
Calls
$9.8​M
Puts
$6.42​M
Net Calls
+$3.35​M
Net Calls Change
+$4.96​M

SANA Hedge Fund Activity: Q3 2024 in Review

155 of the 6,991 institutional investors tracked by Wall St. Rank reported a position in Sana Biotechnology (SANA) for Q3 2024, worth a combined $639M — down 21% from $810M a quarter earlier.

Buyers outnumbered sellers: 32 funds opened new SANA positions and 25 closed out — a net gain of 7 holders — while 42 added to existing stakes and 45 trimmed.

The largest buyer was Fidelity Investments, adding an estimated $23.3M. The largest seller was T. Rowe Price Investment Management, cutting an estimated $6.22M.

  • 155 institutional investors held Sana Biotechnology (SANA) as of Q3 2024, up from 149 in Q2 2024.
  • Funds reported $639M of Sana Biotechnology stock for Q3 2024, down 21% quarter-over-quarter.
  • 32 funds opened new Sana Biotechnology positions in Q3 2024 and 25 closed out, a net change of +7 holders.
  • The largest Sana Biotechnology buyer in Q3 2024 was Fidelity Investments, an estimated $23.3M added.
  • The largest Sana Biotechnology seller in Q3 2024 was T. Rowe Price Investment Management, an estimated $6.22M sold.

Based on aggregated 13F filings for Q3 2024.